FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

SPOTLIGHT: Erbitux ok'd as front-line colon cancer drug


The FDA has approved an Erbitux label update to include additional survival data. ImClone and Bristol-Myers Squibb, who make the drug, announced back in January that research indicated Erbitux proved effective as a front-line therapy against colon cancer. Release

More stories about FDA   ImClone   Erbitux   Bristol-Myers Squibb   colon cancer  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 8 + 16?
To combat spam, please solve the math question above.